Alere Inc  

(Public, NYSE:ALR)   Watch this stock  
Find more results for ALR
51.26
-0.63 (-1.21%)
Sep 4 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 50.98 - 51.83
52 week 34.79 - 55.99
Open 51.26
Vol / Avg. 234,720.00/662,377.00
Mkt cap 4.45B
P/E     -
Div/yield     -
EPS -1.50
Shares 85.54M
Beta 1.75
Inst. own 101%
Oct 26, 2015
Q3 2015 Alere Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Aug 21, 2015
Alere Inc Annual Shareholders Meeting (Estimated)
Aug 12, 2015
Alere Inc at Canaccord Genuity Growth Conference
Aug 4, 2015
Q2 2015 Alere Inc Earnings Release
Aug 4, 2015
Q2 2015 Alere Inc Earnings Call
Jul 22, 2015
Alere Inc Annual Shareholders Meeting
Jun 9, 2015
Alere Inc at Goldman Sachs Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 3.00% -7.48%
Operating margin 14.60% 3.81%
EBITD margin - 11.14%
Return on average assets 1.18% -2.82%
Return on average equity 3.89% -14.27%
Employees 9,800 -
CDP Score - -

Address

51 Sawyer Rd Ste 200
WALTHAM, MA 02453-3448
United States - Map
+1-781-6473900 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alere Inc. is a provider of health information through diagnostic tests. The Company operates through professional diagnostics, patient self-testing, consumer diagnostics and, corporate and other segments. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The patient-self testing segment provides services designed to provide physicians with actionable data that allow them to make decisions in real time, deliver care, and put the individuals they treat on a pathway to better health. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its 50/50 joint venture with The Procter & Gamble Company (P&G).

Officers and directors

Gregg J. Powers Independent Chairman of the Board
Age: 52
Bio & Compensation  - Reuters
Namal Nawana President, Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
James F. Hinrichs Chief Financial Officer, Executive Vice President
Age: 47
Bio & Compensation  - Reuters
Daniella Cramp Global President - Cardiometabolic Business Unit
Age: 41
Bio & Compensation  - Reuters
Sanjay Malkani Global President - Toxicology
Age: 45
Bio & Compensation  - Reuters
Avi Pelossof Global President - Infectious Disease Business Unit
Age: 52
Bio & Compensation  - Reuters
Ellen Chiniara Senior Vice President, General Counsel, Chief Ethics and Compliance Officer and Secretary
Age: 56
Bio & Compensation  - Reuters
John Bridgen Ph.D. Senior Vice President - Business Development
Age: 68
Bio & Compensation  - Reuters
Mark Gladwell Senior Vice President - Global Operations
Age: 40
Bio & Compensation  - Reuters
Melissa Guerdan Senior Vice President - Global Quality and Regulatory Assurance
Age: 41
Bio & Compensation  - Reuters